Health TrialsbyHealthPanel

A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042

ConditionPharmacokinetics
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-65
SponsorAhn-Gook Pharmaceuticals Co.,Ltd

About this trial

The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

A healthy adults aged 19-65 years at the time of screening

Subjects who are deemed eligible based on the screening tests

Disqualifiers

Subjects who have taken the investigational drug within 6 months prior to the first dose

Other exclusions have been applied

Trial design

Design model

Crossover

Treatments tested in this trial

  • AG2304

    Drug

    AG2304, Single-dose Oral Administration

  • AG23041 and AG23042

    Drug

    AG23041/AG23042, Single-dose Oral Administration

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Sequence AExperimental treatment 2 interventions
Group B: Sequence BActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

AUC

Area under the plasma concentration

Time frame
Pharmacokinetic plasma samples collected over a 72-hour period
2

Cmax

Peak Plasma Concentration

Time frame
Pharmacokinetic plasma samples collected over a 72-hour period

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ahn-Gook Pharmaceuticals Co.,Ltd

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: